It has been awhile since I talked about Filament Health and the psychedelics sector in general. In my last post, I left readers in suspense as I shared a…
2021 psychedelics stocks
Standardizing Psychedelic-Assisted Therapy $25.537M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has entered into a licensing agreement with ATMA Journey Centers. Under the agreement, Filament has…
Problematic Psychedelics? Psychedelics and mental health treatment go together like orange juice and toothpaste. That’s what I would have said five years ago. Prior to the publication of multiple…
Psychedelics have showed tremendous potential in treating neurological conditions such as major depressive disorder, PTSD, ALS, and generalized anxiety. Investors jumped on the opportunity, sending market values skyrocketing. It’s…
SPL026 Small Pharma (DMT.V) is a London-based psychedelics company focusing on DMT-assisted psychotherapy for depression, and they’re already doing Phase 1 clinical trials, with Phase 2 on the…
A different approach to MDD I’m big on companies having a unique approach to whatever they are doing. Many psychedelics companies are targetting depression but from a psychedelic-assisted therapy…
It’s 2031, COVID is long gone. Jose Conseco is president of the USA. Jeff Bezos redesigns the human digestive system to not need food or water Peter Thiel spends…